Equillium, Inc. (EQ) Stock: A Strong Pick In The Biotech Space?

0

Equillium, Inc. (EQ) is trending down in the market today. The stock, one that is focused in the biotechnology space, is presently priced at $6.91 after tumbling -5.47% so far in today’s session. When it comes to biotechnology companies, there are several factors that have the potential to cause declines in the market. News is one of the most common reasons for movement. Here are the recent trending headlines relating to EQ:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-26-19 04:07PM Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
Feb-21-19 04:07PM Equillium to Present at Leerink Partners Global Healthcare Conference
Feb-19-19 04:07PM Equillium to Host Business Update Call on February 26
Feb-07-19 08:08AM Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
Dec-19-18 08:06AM Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease

Nonetheless, any time investors are making a decision to invest, prospective investors should focus on far more than news, especially in the generally speculative biotechnology industry. Here’s what’s happing when it comes to Equillium, Inc..

Recent Movement Out of EQ

Although a single session decline, like the move that we’re seeing from Equillium, Inc. might lead to fear in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s generally a good idea to take a look at trends experienced by the stock beyond a single trading session. In the case of EQ, here are the returns that we have seen:

  • Past Seven Days – Over the past 7 days, EQ has generated a change in price amounting to -3.36%.
  • Past Month – The return from Equillium, Inc. over the last 30 days works out to 14.40%.
  • Quarterly – In the past 3 months, the stock has generated a ROI of -37.41%
  • Past Six Months – In the previous 6 months, investors have seen a performance that works out to 0 from the stock.
  • YTD – Since the open of this year EQ has produced a ROI of -15.32%.
  • Annually – Lastly, over the past year, investors have seen performance amounting to 0 out of EQ. Over this period of time, the stock has traded at a high price of -64.91% and a low price of 25.64%.

Rations That Investors Should Look Into

Looking at various key ratios associated with a company generally gives prospective traders an understanding of just how dangerous and/or rewarding a pick may be. Here are a few of the important ratios to look at when looking at EQ.

Short Ratio – The short ratio is a tool that is used by traders to get an understanding of the level of short interest. The higher this ratio, the more investors have a belief that the price of the stock is going to tumble. Across the sector, biotechnology stocks can have a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, when it comes to Equillium, Inc., it’s short ratio clocks in at 8.83.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Essentially, they measure If a company is able to pay for its debts when they mature with only current assets or quick assets. In the biotech space, several companies are reliant on continued support from investors, these ratios can seem upsetting. However, some gems in the biotechnology sector do have positive current and quick ratios. When it comes to EQ, the quick and current ratios come to 1.90 and 1.90 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets that are owned by the company. In this particular case, that ratio equates to -0.93.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the value of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotechnology space, this is a very important ratio to consider. In terms of EQ, the cash to share value ratio comes to 0.30.

How Analysts Feel About Equillium, Inc.

While it’s never a good idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their opinions to validate your own opinions before making an investment decision in the biotech sector. Below you’ll find the recent moves that we’ve seen from analysts as it relates to EQ.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-22-19 Initiated SVB Leerink Outperform $16

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in EQ, here’s what we’re seeing:

  • Institutions – At the moment, institutions own 27.10% of EQ. On the other hand, it’s important to consider that institutional ownership has changed in the amount of 0 over the past quarter.
  • Insiders – When it comes to insiders, those close to the company currently hold 21.30% of Equillium, Inc.. Insider ownership of the company has moved 0 in the last quarter.

Interested In How Many Shares Are Available?

Investors and traders seem to like to know the total numbers of shares both outstanding and available. When it comes to Equillium, Inc., currently there are 16.85M with a float of 6.34M. This means that out of the total of 16.85M shares of EQ in existence today, 6.34M are available to be traded by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to EQ, the short percent of the float is 4.37%.

What We’ve Seen In earnings results

What have ween seen from EQ in terms of financial results?Here is the data:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts are expecting that EQ will create EPS coming to a total of -1.33, with -0.29 being reported in the report for the current quarter. Although this information isn’t associated with earnings, because we’re talking on the topic of Wall St. analysts, EQ is currently graded as a 1.00 when rated on a scale from 1 to 5 where 1 is the poorest Wall Street analyst rating and 5 is the best.
  • 5-Year Sales – Over the last half decade, Equillium, Inc. has generated a change in sales volume that works out to be 0. Earnings in the past 5 years have seen movement in the amount of 0.
  • Q/Q – In terms of quarter over quarter earnings data, or Q/Q data as it is generally referred to as in today’s society, the company has generated a change in earnings that amounts to -632.80%. Equillium, Inc. has also experienced movement in terms of revenue that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I’m heavily dependent on humans. After all, humans built me! Even though my creator enabled me to learn on my own, it is much simpler to learn when I receive feedback from humans. At the bottom of this article, you’ll see a section for comments. If you would like for me find other data, update the way provide data, take a look at data from a different perspective, or you’re interested in telling me anything else, I’d like to know. Please take a moment to leave a comment below. I’ll process your comment and it will help me become a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here